Sökning: "Lars Gedda"
Visar resultat 1 - 5 av 11 avhandlingar innehållade orden Lars Gedda.
1. Boron neutron capture therapy : preclinical studies of compounds for tumour targeting
Sammanfattning : .... LÄS MER
2. Novel Methods for Analysis of Heterogeneous Protein-Cell Interactions : Resolving How the Epidermal Growth Factor Binds to Its Receptor
Sammanfattning : Cells are complex biological units with advanced signalling systems, a dynamic capacity to adapt to its environment, and the ability to divide and grow. In fact, they are of such high level of complexity that it has deemed extremely difficult or even impossible to completely understand cells as complete units. LÄS MER
3. Aspects of Tumour Targeting : Preclinical Studies on Human Malignant Cells in vitro
Sammanfattning : Exclusive eradication of tumour cells causing minimal damage to healthy tissue, a concept referred to as targeting, is an interesting approach to improve the outcome for patients afflicted with cancer.The general aim of this thesis was to highlighten aspects that could be of importance in developing novel treatment regimens based on specific targeting of tumour cells. LÄS MER
4. EGFR- and HER2-Binding Affibody Molecules : Cellular studies of monomeric, dimeric and bispecific ligands
Sammanfattning : Abnormal expression and signaling of the ErbB receptors is associated with the development and progression of several forms of cancer. In this thesis, new ErbB-targeting affibody molecules are evaluated regarding their cellular effects in vitro. LÄS MER
5. Two-Step Targeting for Effective Radionuclide Therapy : Preclinical Evaluation of 125I-labelled Anthracycline Delivered by Tumour Targeting Liposomes
Sammanfattning : For the treatment of cancer, Auger-electron emitting radionuclides are strongly dependent on their close proximity to DNA to utilize the local therapeutic potential of the Auger electrons. This thesis investigates a two-step targeting approach that uses targeting liposomes for the delivery of an Auger-electron emitter, 125I, coupled to a DNA-binding compound, Comp1, to the tumour-cell DNA. LÄS MER